Cereno Scientific strengthens its Executive Management Team with Head of Clinical Operations
Cereno Scientific (XSAT: CRNO B) today announced the recruitment of Fredrik Frick as Head of Clinical Operations. The appointment adds another experienced research and development (R&D) executive to Cereno’s management team, thereby further strengthens the R&D organization as the Company’s pipeline builds and progresses through preclinical and clinical studies.
“The development of our pipeline is a critical success factor for Cereno in order to deliver on our vision to make available innovative drugs for patients with rare and common cardiovascular diseases. I am therefore delighted that we have complemented and strengthen our management team with additional leadership expertise and capacity in this area,” says Sten R. Sörensen, CEO at Cereno Scientific. “I believe Fredrik will be a great addition to our team with his proven track record of working with all facets of drug development.”
As Head of Clinical Operations, Fredrik Frick will be responsible for all Cereno’s clinical activities globally, providing leadership, project management and program oversight for the preparation and execution of international clinical development programs. Fredrik has a PhD in Medical Physiology/Endocrinology and holds 17 years of collected experience working at AstraZeneca with early- to late-stage drug development including pre-clinical target identification, clinical drug discovery and clinical study management and operations.
Fredrik will join the Executive Management Team no later than May and report to the CEO.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The CS585 program consists of stable, selective, and potent IP (prostacyclin) receptor agonists and the CS014 program comprises HDAC inhibitors with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.